Clinical-stage biotechnology company and University of Zurich spin-off (founded 2015, Schlieren, Switzerland) developing anti-Nogo-A antibody biologics that promote nerve regeneration and functional recovery in central nervous system diseases and injuries, including spinal cord injury, stroke, and secondary progressive multiple sclerosis. Its lead candidate NG004, developed in collaboration with Neurimmune, completed promising Phase 1 results and is being advanced into a proof-of-concept trial in acute spinal cord injury.
1
Round
1
Industry
4
Tags
Sep 2, 2026
Latest raise
Funding activity · 1 round
Sep 2, 2026
CHF 24M
Series B
Led by Pureos Bioventures
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
